ProJect Pharmaceutics is delighted to expand the global presence of its service portfolio towards the Asian market. Entering into a collaboration with business partner BiGEN in South Korea, ProJect Pharmaceutics becomes a cross-country competence hub for formulation and process development. On top, ProJect Pharmaceutics can now offer its clients to act as a gate opener
ProJect Pharmaceutics expands its service portfolio to meet customer’s increasing need for the development of GMO S2 and BSL-2 biological products including live viruses. ProJect Pharmaceutics is one of the leading European service providers offering tailored pharmaceutical formulations and lyophilisation processes for therapeutic proteins, peptides and other therapeutic compounds. New safety facilities in dedicated labs
ProJect Pharmaceutics enters collaboration with German CMO as the preferred development partner for lyophilization
ProJect Pharmaceutics is a contract research and development organization (CRO) specialized in formulation and process development for parenteral drug products. Adjacent to its service portfolio, ProJect Pharmaceutics operates a broad network towards contract manufacturing organizations (CMOs) for drug substance and drug product to support its clients towards selecting the best fit for their products’ manufacturing
ProJect Pharmaceutics is glad to announce its participation as exhibitor at the upcoming World ADC Conference, taking place in Berlin, Germany, February 21-23, 2017. The conference will bring together international experts on ADCs from industries, universities and CROs.
Munich, October 29, 2015 – ProJect Pharmaceutics introduces a science-based approach to develop best-in-class formulations for convenient use in pre-filled syringes Transforming therapeutic proteins into high-concentrated, stable and easy to use medications for subcutaneous self-injection can add up to a major challenge along their clinical development. A formulation’s fundamental qualifications such as appropriate physico-chemical stability,